GO 14C9
Alternative Names: GO-14C9Latest Information Update: 04 Feb 2021
At a glance
- Originator GO Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Colorectal cancer; Gastric cancer; Liver cancer; Oesophageal cancer
Most Recent Events
- 22 Jan 2021 Early research in Colorectal cancer in USA (Parenteral) before January 2021 (GO Therapeutics pipeline, January 2021)
- 22 Jan 2021 Early research in Gastric cancer in USA (Parenteral) before January 2021 (GO Therapeutics pipeline, January 2021)
- 22 Jan 2021 Early research in Liver cancer in USA (Parenteral) before January 2021 (GO Therapeutics pipeline, January 2021)